#XCUR hashtag - Bluesky

Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating burixafor (GPC-100) in combination with

3 months ago

#XCUR Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting

www.stocktitan.net/news/XCUR/exicure-presen...

0 0 0 0

Exicure, Inc. Reports Third Quarter 2025 Financial Results Exicure (Nasdaq: XCUR) reported third quarter 2025 results for the quarter ended September 30, 2025.Key figures: cash and cash equivalents $4.4M (Sept 30, 2025 vs $12.5M on Dec 31, 2024), R&D $0.9M, G&A $1.5M, and net loss $2.4M for Q3 2025. The company recorded a $246K loss from a contingent liability change and a $155K gain related to a self-insured retainer settlement.Management stated cash is not sufficient to fund operations and said substantial additional financing is needed in the short term.

4 months ago

#XCUR Exicure, Inc. Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/XCUR/exicure-inc-re...

0 0 0 0

5 months ago

#XCUR New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting

www.stocktitan.net/news/XCUR/new-burixafor-...

0 0 0 0

Exicure Highlights Recent Achievements and Near-term Strategic Priorities Exicure (Nasdaq: XCUR) reported progress on its lead program burixafor (GPC-100), highlighting that an ongoing Phase 2 multiple myeloma study achieved the primary endpoint in all evaluable patients (10/10) and that the clinical database is locked with topline data expected in Q4 2025. The company is preparing for potential Phase 3 planning and expanding development into sickle cell disease (investigator-sponsored trial discussions) and a planned Phase 1 AML chemosensitization study. Exicure also announced new senior drug-development hires to support clinical and translational execution.

5 months ago

#XCUR Exicure Highlights Recent Achievements and Near-term Strategic Priorities

www.stocktitan.net/news/XCUR/exicure-highli...

0 0 0 0

Exicure, Inc. Reports Second Quarter 2025 Financial Results Exicure (Nasdaq: XCUR) reported Q2 2025 financial results, highlighting significant challenges in its financial position. The company's cash and cash equivalents decreased to $7.9 million as of June 30, 2025, down from $12.5 million at the end of 2024.Following the acquisition of GPCR Therapeutics USA, R&D expenses increased to $0.9 million (from $0 in Q2 2024), while G&A expenses rose to $1.5 million (from $1.2 million). The company reported a net loss of $2.6 million for Q2 2025, significantly higher than the $0.6 million loss in Q2 2024.Management has expressed serious concerns about the company's ability to continue operations, stating that current cash reserves are insufficient and substantial additional financing is urgently needed.

7 months ago

#XCUR Exicure, Inc. Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/XCUR/exicure-inc-re...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

8 months ago

Leading Indicators, Monday August 4, 2025 – Crystal Equity Research

Small-cap stocks with strong volume gains, Mon Aug 4th - #ZYXI #XCUR #PPIH #NAAS #LFMD #INMP #GP #EVTV #DRCI #COMM #BTAI #ATLX #SCS #LUXE #ELME #DAO #CCO - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

HumanAlgoHybrid

@humanalgohybrid.bsky.social

8 months ago

Top after-hours breakouts in penny stocks for Friday, August 01, 2025 sorted by range are $XCUR $8.2 (19%), $SEMR $9.45 (11%), $TMC $6.88 (17%), $ABAT $2.38 (8%) #XCUR #chartanalysis #gappers #daytrading

0 0 0 0

Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant Exicure (Nasdaq: XCUR) has completed the last patient visit in its Phase 2 clinical trial evaluating GPC-100 (burixafor) for stem cell mobilization in multiple myeloma patients. The study assesses GPC-100's ability to improve CD34+ hematopoietic stem cell mobilization for autologous stem cell transplant (ASCT).Key highlights include GPC-100's differentiated rapid mobilization time of just 45 minutes before collection, compared to traditional overnight procedures. The company expects topline results in Q4 2025. Beyond multiple myeloma, Exicure plans a Phase 1 study in acute myeloid leukemia and is exploring potential collaborations for cell and gene therapy applications.

8 months ago

#XCUR Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

www.stocktitan.net/news/XCUR/exicure-comple...

1 0 0 0

Exicure, Inc. Reports First Quarter 2025 Financial Results Exicure (Nasdaq: XCUR) reported Q1 2025 financial results, posting a net income of $3.0 million compared to a net loss of $0.8 million in Q1 2024. The company's cash position stood at $10.4 million as of March 31, 2025, down from $12.5 million at the end of 2024.The quarter's performance was primarily driven by a $6 million gain from early lease termination in Chicago, offset by increased operating expenses following the GPCR USA acquisition. R&D expenses increased to $0.8 million, while G&A expenses rose to $2.2 million.Notably, management expressed significant concern about the company's financial sustainability, stating that current cash reserves are insufficient to fund ongoing operations and substantial additional financing is urgently needed.

9 months ago

#XCUR Exicure, Inc. Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/XCUR/exicure-inc-re...

0 0 0 0

9 months ago

Just In: ( NASDAQ: #XCUR ) XCUR - Historical Earnings Price Analysis

0 0 0 0

9 months ago

NEWS: ( NASDAQ: #XCUR ) XCUR - Historical Price Movements Surrounding Earnings

0 0 0 0

Exicure Faces Nasdaq Delisting Risk: 60 Days to Submit Compliance Plan for Late Q1 Filing Latest Nasdaq warning gives Exicure 60 days to file compliance plan for Q1 2025 report delay. Company could get 180-day extension. See timeline details.

10 months ago

#XCUR Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q

www.stocktitan.net/news/XCUR/exicure-inc-re...

0 0 0 0

10 months ago

JUST IN: ( NASDAQ: #XCUR ) (XCUR) Investment Report

0 0 0 0

Breakthrough Multiple Myeloma Treatment: Exicure's Phase 2 Trial Fully Enrolled, Results Coming Fall 2025 Novel GPC-100 therapy shows promise in stem cell mobilization for multiple myeloma patients. Phase 2 trial explores improved transplant outcomes. See full enrollment data.

10 months ago

#XCUR Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant

www.stocktitan.net/news/XCUR/exicure-comple...

1 0 0 0

Breakthrough: New Multiple Myeloma Treatment Achieves Perfect Success Rate in Trial Latest data reveals GPC-100's same-day stem cell mobilization success in multiple myeloma patients, offering faster treatment than current FDA-approved options.

11 months ago

#XCUR Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma

www.stocktitan.net/news/XCUR/exicure-inc-na...

0 0 0 0

Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML) Exicure (XCUR) has announced plans for a new clinical trial of its lead asset GPC-100 (burixafor) in Acute Myeloid Leukemia (AML). The CXCR4 inhibitor has shown promise when combined with modern AML treatments. A previous Phase 1 study with 15 relapsed/refractory AML patients evaluated GPC-100's safety and preliminary efficacy in combination with fludarabine and cytarabine.Recent preclinical data presented at the 2024 ASH Annual Meeting demonstrated improved chemotherapy response through dual inhibition of CXCR4 with GPC-100 and beta-2 adrenergic receptor blockade. The company has secured patents for this approach in multiple countries.GPC-100 is currently in a Phase 2 trial for multiple myeloma patients undergoing autologous stem cell transplant, with results expected in Q4 2025. Exicure is also exploring potential expansions into sickle cell disease, pediatric oncology, and cell and gene therapy applications.

11 months ago

#XCUR Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)

www.stocktitan.net/news/XCUR/exicure-inc-na...

0 0 0 0

Exicure's Survival at Risk Despite $12.5M Cash Position in 2024 Results Exicure ends 2024 with $12.5M cash but faces operational uncertainty. Zero R&D spending and 42% lower losses reflect complete research suspension as company seeks strategic alternatives.

1 year ago

#XCUR Exicure, Inc. Reports Full Year 2024 Financial Results

www.stocktitan.net/news/XCUR/exicure-inc-re...

0 0 0 0

Exicure's New Cancer Patent Breakthrough Powers Multiple Myeloma Clinical Trial Exicure strengthens global IP portfolio with Australian patent for innovative GPCR cancer therapy, advancing Phase 2 trial in multiple myeloma treatment development.

1 year ago

#XCUR Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia

www.stocktitan.net/news/XCUR/exicure-inc-na...

0 0 0 0

1 year ago

JUST IN: ( NASDAQ: #XCUR ) (XCUR) Technical Pivots with Risk Controls

0 0 0 0

1 year ago

BREAKING NEWS: ( NASDAQ: #XCUR ) Exicure Inc. (NASDAQ: XCUR) Rises Sharply in 3/4 Early Trading Session

0 0 0 0

Exicure Acquires GPCR Therapeutics USA, Signs Major Licensing Deal for Drug Development Exicure expands portfolio through GPCR Therapeutics USA acquisition and inks collaboration agreement with milestone-based structure, including 10% royalty on future net sales.

1 year ago

#XCUR Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.

www.stocktitan.net/news/XCUR/exicure-inc-an...

0 0 0 0

Exicure (XCUR) to Acquire GPCR USA, Gains Phase 2 Cancer Drug Pipeline with $2B Market Potential Exicure secures $12M funding to acquire GPCR USA, gaining rights to CXCR4 inhibitor in Phase 2 trials for multiple myeloma and AML treatment. Additional $4M funding expected.

1 year ago

#XCUR Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech

www.stocktitan.net/news/XCUR/exicure-inc-pa...

0 0 0 0

Exicure Secures $12M Strategic Investment as HiTron Systems Takes Majority Stake Exicure lands major financing deals totaling $12M, with HiTron Systems becoming majority shareholder. Company addresses Nasdaq compliance with fresh capital injection.

1 year ago

#XCUR Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes

www.stocktitan.net/news/XCUR/exicure-inc-an...

0 0 0 0